Skip to content
Research Article Open access CC BY 4.0

Management of Disseminated Intravascular Coagulation in Emergency: A Review

Hisham Mohammed Sonbul, Abdulrahman Mohammed S. Alabid, Fahad Ali A. Almarshad, Alqahtani, Ali Saad M., Rayan Ali Barakat, Abudeyah, Manal Ahmed K., Ameera Jassim A. Al Ramadhan, Muteb Bandar Binmohaiya, Alqarni, Alwaled Abdullah B., Hayash, Fatimah Abdulrahman H., Abdulelah Ahmed Alabdulwahab

Journal of Pharmaceutical Research International · pp. 1–9 · Published 18 Oct 2021

10.9734/jpri/2021/v33i46B32908

Abstract

Disseminated intravascular coagulation (DIC) is life threatening disease it’s often associated with sepsis, which require ICU management. In individuals with sepsis, the risk of DIC is especially high, DIC affects 30 to 50 percent of these individuals. Also it affects only about ten percent of patients with solid tumors, trauma, or obstetric emergencies. Hematological malignancies, aneurysms, and liver diseases can also cause the disease, the treatment for DIC focuses on resolving the underlying problem that led to this condition in the first place. As a result, antibiotics for severe sepsis, delivery in the case of placental abruption, and exploratory surgical intervention in the case of trauma are the pillars of DIC treatment, Patients with active bleeding or a high risk of bleeding, as well as those who require an invasive surgery, should consider platelet and plasma transfusions. Other anti-coagulant drugs can also be used. Prothrombin complex concentrates should only be administered in an emergency, due to their possible dangers. Recombinant human soluble thrombomodulin rhTM it was developed and licensed for clinical usage in Japan in 2008, and it’s one of the novel treatments for DIC. Anti-Xa agents, Synthetic protease inhibitors, and antithrombin are another options for treatment. In this article we will be making overview of the disease, it’s etiology an what’s the current management options. 

Disseminated intravascular coagulation (DIC) ICU management anti-coagulant drugs recombinant human soluble thrombomodulin rhTM

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.